Remission of Nonparaneoplastic Autoimmune Retinopathy After Minimal Steroid Treatment
Overview
Affiliations
Purpose: To describe the clinical findings in a patient demonstrating recovery from nonparaneoplastic autoimmune retinopathy after a minimal course of steroid treatment.
Methods: Clinical presentation was documented, and paraclinical tests were obtained using Humphrey automated perimetry for visual fields, Western blotting for antiretinal antibodies, and electroretinography for evaluation of rod and cone function.
Results: Initial presentation revealed marked visual field deficits, electroretinographic dysfunction, and the presence of α-enolase autoantibodies. After a brief course of oral corticosteroids, the patient demonstrated improvement in visual fields, disappearance of α-enolase autoantibodies, partial recovery of the cone on-response, and complete recovery of the rod response.
Conclusion: This case is distinguished from previous reports by the rapidity and degree of recovery, the brevity of treatment required, and the unique electroretinographic recovery pattern with concomitant disappearance of α-enolase autoantibodies. These findings suggest a pathologic role for α-enolase autoantibodies in autoimmune rod bipolar cell dysfunction. Identification of other cases exhibiting such improvements and associated autoantibody activity may expand our understanding of nonparaneoplastic autoimmune retinopathy disease pathogenesis.
Kapoor I, Sarvepalli S, Grewal D, Hadziahmetovic M Ophthalmol Sci. 2024; 5(1):100622.
PMID: 39669695 PMC: 11635770. DOI: 10.1016/j.xops.2024.100622.
Autoantibody profiles and clinical association in Thai patients with autoimmune retinopathy.
Pawestri A, Arjkongharn N, Suvannaboon R, Tuekprakhon A, Srimuninnimit V, Udompunthurak S Sci Rep. 2021; 11(1):15047.
PMID: 34294798 PMC: 8298708. DOI: 10.1038/s41598-021-94377-0.
An update on autoimmune retinopathy.
Dutta Majumder P, Marchese A, Pichi F, Garg I, Agarwal A Indian J Ophthalmol. 2020; 68(9):1829-1837.
PMID: 32823399 PMC: 7690499. DOI: 10.4103/ijo.IJO_786_20.
Sen H, Grange L, Akanda M, Fox A Trans Am Ophthalmol Soc. 2018; 115:T8.
PMID: 29576753 PMC: 5844289.
Adamus G Front Immunol. 2017; 8:505.
PMID: 28503176 PMC: 5408022. DOI: 10.3389/fimmu.2017.00505.